Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database.
Fiche publication
Date publication
octobre 2021
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALAC Sophie, Dr GRANEL-BROCARD Florence
Tous les auteurs :
Bassompierre A, Dalac S, Dreno B, Neidhardt EM, Maubec E, Capelle C, Andre F, Behal H, Dziwniel V, Bens G, Leccia MT, Meyer N, Granel-Brocard F, Beylot-Barry M, Dereure O, Basset-Seguin N, Mortier L
Lien Pubmed
Résumé
Smoothened (SMO) inhibitors, blocking the sonic hedgehog pathway, have been approved for advanced basal cell carcinoma (aBCC). Safety analyses reveal a high rate of adverse events (AEs) and, most of the time, vismodegib is most commonly stopped when the best overall response is reached. The long-term evolution of aBCC after vismodegib discontinuation is poorly described. The aim of this study is to evaluate the efficacy and safety of the SMO inhibitors (SMOis) available (vismodegib and sonidegib) following rechallenge after complete response (CR) following an initial treatment by vismodegib.
Mots clés
CARADERM, SMO inhibitor, advanced BCC, rechallenge, recurrence, relapse, resistance, retreatment, vismodegib
Référence
ESMO Open. 2021 Oct 21;6(6):100284